SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells

Yongfa Li1, Shenghu Zhang2, Min Peng3

  • 1Department of Oncology, Xinkang Hospital of Renmin Hospital of Wuhan University, Wuhan, 430000, Hubei, P.R. China.

Abstract

Insights

Sphingomyelin synthase 1 (SMS1) helps ovarian cancer cells resist platinum chemotherapy by maintaining lysosomal function. Targeting SMS1 could improve treatment effectiveness against ovarian cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Platinum chemotherapy resistance is a key challenge in ovarian cancer treatment.
  • The role of sphingomyelin synthases (SMS1 and SMS2) in chemotherapy response is not well understood.

Purpose of the Study:

  • To investigate the roles of SMS1 and SMS2 in platinum chemotherapy sensitivity in ovarian cancer.
  • To explore the molecular mechanisms by which SMS1 and SMS2 affect chemotherapy response.

Main Methods:

  • Assessed SMS1 and SMS2 expression in ovarian cancer cells after chemotherapy exposure.
  • Utilized gain- and loss-of-function studies to evaluate effects on cell proliferation, apoptosis, and chemotherapy sensitivity.
  • Performed biochemical assays to elucidate underlying mechanisms.

Main Results:

  • Cisplatin selectively increased SMS1 expression, while SMS1/SMS2 silencing enhanced sensitivity to cisplatin and paclitaxel.
  • SMS1 overexpression protected cells from apoptosis, linked to lysosomal impairment and oxidative injury.
  • High SMS1 expression correlated with poorer patient outcomes, especially with Taxol plus platinum chemotherapy.

Conclusions:

  • SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer.
  • SMS1 acts as a platinum-induced resistance factor, supporting tumor cell survival via lysosomal homeostasis.
  • Targeting SMS1 may enhance platinum chemotherapy efficacy in ovarian cancer.